Document Detail


Sympathetic activation and nitric oxide function in early hypertension.
MedLine Citation:
PMID:  22287587     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to determine if tonic restrain of blood pressure by nitric oxide (NO) is impaired early in the development of hypertension. Impaired NO function is thought to contribute to hypertension, but it is not clear if this is explained by direct effects of NO on vascular tone or indirect modulation of sympathetic activity. We determined the blood pressure effect of NO synthase inhibition with N(ω)-monomethyl-l-arginine (L-NMMA) during autonomic blockade with trimethaphan to eliminate baroreflex buffering and NO modulation of autonomic tone. In this setting, impaired NO modulation of vascular tone would be reflected as a blunted pressor response to L-NMMA. We enrolled a total of 66 subjects (39 ± 1.3 yr old, 30 females), 20 normotensives, 20 prehypertensives (blood pressure between 120/80 and 140/90 mmHg), 17 hypertensives, and 9 smokers (included as "positive" controls of impaired NO function). Trimethaphan normalized blood pressure in hypertensives, suggesting increased sympathetic tone contributing to hypertension. In contrast, L-NMMA produced similar increases in systolic blood pressure in normal, prehypertensive, and hypertensive subjects (31 ± 2, 32 ± 2, and 30 ± 3 mmHg, respectively), whereas the response of smokers was blunted (16 ± 5 mmHg, P = 0.012). Our results suggest that sympathetic activity plays a role in hypertension. NO tonically restrains blood pressure by ∼30 mmHg, but we found no evidence of impaired modulation by NO of vascular tone contributing to the early development of hypertension. If NO deficiency contributes to hypertension, it is likely to be through its modulation of the autonomic nervous system, which was excluded in this study.
Authors:
Alfredo Gamboa; Luis E Okamoto; André Diedrich; Leena Choi; David Robertson; Ginnie Farley; Sachin Paranjape; Italo Biaggioni
Related Documents :
16572267 - Genetic variation at the growth hormone (gh1) and growth hormone receptor (ghr) loci as...
11773937 - Familial aggregation of seven-year changes in blood pressure in canada.
24691347 - Intraoperative management of free flaps: current practice.
19609347 - A genome-wide association study of hypertension and blood pressure in african americans.
1658137 - Stiffness of the common carotid artery in treated hypertensive patients.
8828767 - Extracting 1/f fluctuation from the arterial blood pressure of an artificial heart.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-01-27
Journal Detail:
Title:  American journal of physiology. Heart and circulatory physiology     Volume:  302     ISSN:  1522-1539     ISO Abbreviation:  Am. J. Physiol. Heart Circ. Physiol.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-04-02     Completed Date:  2012-05-15     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  100901228     Medline TA:  Am J Physiol Heart Circ Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  H1438-43     Citation Subset:  IM    
Affiliation:
Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA. alfredo.gamboa@vanderbilt.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aging / physiology
Baroreflex / drug effects
Blood Pressure / drug effects,  physiology
Enzyme Inhibitors / pharmacology
Female
Heart Rate / drug effects
Humans
Hypertension / physiopathology*
Male
Middle Aged
Muscle Tonus / drug effects,  physiology
Muscle, Smooth, Vascular / drug effects,  physiology
Nicotinic Antagonists / pharmacology
Nitric Oxide / physiology*
Nitric Oxide Synthase Type III / antagonists & inhibitors
Receptors, Nicotinic / drug effects
Smoking / physiopathology
Sympathetic Nervous System / drug effects,  physiopathology*
Trimethaphan / pharmacology
Young Adult
omega-N-Methylarginine / pharmacology
Grant Support
ID/Acronym/Agency:
K23 HL-95905/HL/NHLBI NIH HHS; K23 HL095905/HL/NHLBI NIH HHS; M01 RR-000095-477450/RR/NCRR NIH HHS; P01 HL-056693-080003/HL/NHLBI NIH HHS; R01 HL-67232/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Nicotinic Antagonists; 0/Receptors, Nicotinic; 10102-43-9/Nitric Oxide; 17035-90-4/omega-N-Methylarginine; 7187-66-8/Trimethaphan; EC 1.14.13.39/Nitric Oxide Synthase Type III
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The onset of left ventricular diastolic dysfunction in SHR rats is not related to hypertrophy or hyp...
Next Document:  Connexin43 ablation in foetal atrial myocytes decreases electrical coupling, partner connexins, and ...